James Gebel Selected Research

Xenon

10/2006

Reduced pretreatment ipsilateral middle cerebral artery cerebral blood flow is predictive of symptomatic hemorrhage post-intra-arterial thrombolysis in patients with middle cerebral artery occlusion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James Gebel Research Topics

Disease

7	Stroke (Strokes) 12/2008 - 04/2002
4	Ischemic Stroke 12/2008 - 02/2004
2	Myocardial Infarction 12/2008 - 02/2005
2	Hypertension (High Blood Pressure) 02/2005 - 05/2002
1	Cerebral Hemorrhage 10/2006
1	Vascular Diseases (Vascular Disease) 01/2005
1	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 05/2002
1	Intracranial Aneurysm (Cerebral Aneurysm) 05/2002

Drug/Important Bio-Agent (IBA)

2	Tissue Plasminogen Activator (Alteplase)FDA Link 12/2008 - 02/2004
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 12/2008
1	Platelet Membrane Glycoprotein IIbIBA 12/2008
1	Eptifibatide (Integrilin)FDA Link 12/2008
1	Glycoproteins (Glycoprotein)IBA 12/2008
1	XenonIBA 10/2006
1	CholesterolIBA 02/2005
1	Oxygen (Dioxygen)IBA 01/2005
1	Acetazolamide (Diamox)FDA LinkGeneric 01/2005
1	Apolipoprotein E4IBA 05/2002
1	Apolipoprotein E2IBA 05/2002

Therapy/Procedure

2	Transplantation 07/2005 - 02/2003
2	Therapeutics 05/2002 - 04/2002
1	Thrombolytic Therapy 10/2006
1	Stroke Rehabilitation 07/2005
1	Contraindications 07/2005